Translation. Region: Russian Federal
Source: Novosibirsk State University –
An important disclaimer is at the bottom of this article.
I.M. Sechenov First Moscow State Medical University and Novosibirsk State University (NSU) have signed an agreement to open a joint clinical research center "West-East". The goal of the strategic partnership between the country's two leading research universities is to organize and conduct clinical research, create breakthrough technologies and innovative drugs for practical healthcare. Vice-Rector for Scientific and Technological Development of the First Moscow State Medical University Vadim Tarasov and Rector of NSU Mikhail Fedoruk signed the document on August 27 at the XII international forum "Technoprom-2025" in Novosibirsk.
The Clinical Research Center of the First Moscow State Medical University and Novosibirsk State University will begin its work in September 2025 and its activities will have two key areas. The first is conducting clinical trials of drugs. Combining the resources of two leading Russian universities will solve the problem of patient recruitment for pharmaceutical companies by coordinating actions in the Western European (based on Sechenov University) and Eastern European (based on NSU) parts of the country.
The second direction is joint exploratory research to create innovative medical technologies. The partners will direct part of the funds received from the commercial activities of the center to their development.
— To implement this strategic direction, we are combining the capabilities of two universities. On the part of Sechenov University, this is medical industry expertise and our unique competencies in the field of drug development and bringing them to market, — Vadim Tarasov commented on the signing of the document. — Our specialists have successfully developed and introduced into production more than 200 drugs, conducted more than 300 preclinical and more than a thousand clinical studies, including studies of the first coronavirus vaccine "Sputnik V". We carry out all stages of drug development – from the stage of molecule selection to the submission of a registration dossier in accordance with Russian and international standards. Together with Novosibirsk State University, we plan to create a system for financing exploratory research at the expense of profits received for conducting clinical trials. We are talking about joint research to create breakthrough medical technologies and innovative drugs using artificial intelligence and X-ray structural analysis of molecules. The combination of these technologies will significantly speed up and reduce the cost of developing innovative drugs.
The Medical Research and Educational Center of the Institute of Medicine and Medical Technologies (IMMT) of NSU will become the platform for the Eastern European segment of the clinical center. The Institute has unique technological platforms and a ready-made research infrastructure, which creates a solid foundation for its development and allows it to begin implementing specific scientific and clinical tasks.
— The infrastructure created at NSU for conducting fundamental research, including the unique educational and research station SKIF-NSU, the construction of which will be completed this year, will allow us to exchange experience, expand the clinical base, initiate new projects, and also shorten the path of a drug from the first phase of clinical trials to the launch of a finished product on the market, — said Yulia Samoilova, Director of the Institute of Medicine and Medical Technologies of NSU.
She also noted that today most clinical trials are conducted in central Russia. Now that a similar center will be created beyond the Urals, new opportunities will appear for expanding cooperation with drug manufacturers from the BRICS countries, Kazakhstan, Uzbekistan, China and India, for whom it is more convenient from a logistical point of view to interact with research centers located in Siberia.
The West-East Center is equipped with all the necessary equipment for conducting clinical research and testing of medical products, including innovative ones that have no analogues on the market. In the future, NSU and Sechenov University plan to launch joint network educational programs in the field of medical and pharmaceutical education, including programs for additional professional education.
Please note: This information is raw content obtained directly from the source of the information. It is an accurate report of what the source claims and does not necessarily reflect the position of MIL-OSI or its clients.
.